VYGR (STOCKS)
Voyager Therapeutics, Inc. Common Stock
$3.223900
+0.023900 (+0.75%)
Prev close: $3.200000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Alfred W. Sandrock
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $210.98M
- Employees
- 172
- P/E (TTM)
- -1.78
- P/B (TTM)
- 1.27
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $34.46M |
| Benefits Costs and Expenses | $142.06M |
| Costs And Expenses | $142.06M |
| Nonoperating Income/Loss | $9.59M |
| Operating Expenses | $151.65M |
| Research and Development | $118.46M |
| Other Operating Expenses | $33.19M |
| Operating Income/Loss | -$117.19M |
| Income/Loss From Continuing Operations After Tax | -$107.73M |
| Income/Loss From Continuing Operations Before Tax | -$107.60M |
| Income Tax Expense/Benefit | $126.00K |
| Net Income/Loss | -$107.73M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$107.73M |
| Net Income/Loss Available To Common Stockholders, Basic | -$107.73M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.81 |
| Diluted Earnings Per Share | -$1.81 |
| Basic Average Shares | 118,911,077 |
| Diluted Average Shares | 118,911,077 |
| Assets | $197.75M |
| Current Assets | $125.23M |
| Cash | $148.80M |
| Accounts Receivable | $2.93M |
| Noncurrent Assets | $72.53M |
| Fixed Assets | $11.19M |
| Other Non-current Assets | $61.33M |
| Liabilities | $43.38M |
| Current Liabilities | $16.69M |
| Accounts Payable | $1.61M |
| Wages | $4.11M |
| Other Current Liabilities | $10.96M |
| Noncurrent Liabilities | $26.69M |
| Equity | $154.38M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $154.38M |
| Liabilities And Equity | $197.75M |
| Net Cash Flow From Operating Activities | -$120.57M |
| Net Cash Flow From Operating Activities, Continuing | -$120.57M |
| Net Cash Flow From Investing Activities | $105.80M |
| Net Cash Flow From Investing Activities, Continuing | $105.80M |
| Net Cash Flow From Financing Activities | $6.46M |
| Net Cash Flow From Financing Activities, Continuing | $6.46M |
| Net Cash Flow | -$8.31M |
| Net Cash Flow, Continuing | -$8.31M |
| Comprehensive Income/Loss | -$107.93M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$107.93M |
| Other Comprehensive Income/Loss | -$28.09M |
| Other Comprehensive Income/Loss Attributable To Parent | -$200.00K |